Poor tumor targeting of oncolytic adenoviruses (OAdv) after systemic administration is considered a major limitation for virotherapy of disseminated cancers. The benefit of using mesenchymal stem cells as cell carriers for OAdv tumor targeting is currently evaluated not only in preclinical models but also in clinical trials. In this context, we have previously demonstrated the enhanced antitumor efficacy of OAdv-loaded menstrual blood-derived mesenchymal stem cells (MenSCs). However, although significant, the antitumor efficacy obtained was modest, and we hypothesized that a greater antitumor efficacy could be obtained arming the OAdv with a therapeutic transgene. Here we show that combining MenSCs with ICOVIR15-cBiTE, an OAdv expressing an epidermal growth factor receptor (EGFR)-targeting bispecific T-cell engager (cBiTE), enhances the antitumor efficacy compared to MenSCs loaded with the unarmed virus ICOVIR15. We found that MenSCs properly produce cBiTE after viral infection leading to a greater antitumor potency both in vitro and in vivo. These findings indicate the mutual benefit of combining MenSCs and armed OAdv and support the combination of ICOVIR15-cBiTE and MenSCs as a cancer treatment.
Introduction
Oncolytic adenoviruses (OAdv) have been extensively studied in clinical trials for the treatment of different cancer types, revealing good toxicological and safety profiles, but modest efficacy [1] . A key limitation upon OAdv systemic administration is virus biodistribution. Poor tumor targeting and limited tumor penetration contribute to such inefficacy [2] . The antiviral immune response also represents an important barrier for OAdv. Thus, the immune system can recognize the adenovirus in the bloodstream leading to its elimination. In particular, neutralizing antibodies raised after the first administration prevent the efficacy of subsequent doses. Moreover, virus replication within the tumor also triggers a potent antiviral response that limits ongoing infection of tumor cells, becoming dominant over tumor-specific immunity [3] .
The use of cell carriers to deliver oncolytic viruses to primary tumors and metastasis has been evaluated in order to overcome these obstacles. In this regard, mesenchymal stem cells (MSCs) have garnered interest as OAdv cell carriers given their natural tumor tropism and immunogenic properties [4] . We have recently reported the advantages of using menstrual blood-derived mesenchymal stem cells (MenSCs) as cell carriers for ICOVIR15, an OAdv developed in our laboratory [5] . We demonstrated not only an efficient OAdv tumor delivery, but also a significant, although modest, antitumor efficacy of OAdv-loaded MenSCs in combination with human peripheral blood mononuclear cells (hPBMCs). This increased antitumor effect was mainly mediated by monocyte activation leading to both T cell and natural killer cell activation [5] .
In a different line of research aimed at redirecting T cells toward tumor cells, we have recently engineered an armed OAdv (ICOVIR15K-cBiTE) expressing an epidermal growth factor receptor (EGFR)-targeting bispecific T-cell engager (cBiTE) [6] . BiTEs are well-established immunotherapeutic molecules that combine the minimal binding domains (scFv) of two different monoclonal antibodies fused by a short flexible linker [7] . One of the scFv recognizes the TCR CD3ε subunit whereas the second scFv targets tumor-associated antigens on cancer cells, leading to T-cell activation and target cell lysis. The major histocompatibility complex class I-independent and polyclonal mode of action of BiTEs [8] , offers the opportunity to redirect adenovirus-specific cytotoxic T lymphocytes to cancer cells. Our work revealed that ICOVIR15K-cBITE induces robust and specific-T cell activation and proliferation upon cancer cell infection, increasing the antitumor efficacy of the virus, both in vitro and in vivo [6] .
Combining these strategies, this study compares the antitumor efficacy of a cBiTE-armed (ICOVIR15-cBiTE) versus the unarmed (ICOVIR15) OAdvs in combination with MenSCs as cells carriers in the presence of hPBMCs. We show that MenSCs properly deliver both OAdvs to the tumor, allowing tumor viral replication and cBiTE production from the armed virus-infected cells. Enhanced antitumor efficacy is observed when the cBiTE-expressing OAdv is combined with MenSCs, demonstrating the potential benefit of using ICOVIR15-cBiTE-loaded MenSCs to improve the treatment outcome.
Materials and methods

Cell lines and viruses
The cancer cell lines A549 (human lung adenocarcinoma) and A431 (epidermoid carcinoma) were obtained from the American Type Culture Collection (ATCC, Manassas, VA). A431-GL was generated by sorting A431 cells previously transduced with a lentiviral vector encoding GFP and luciferase. All tumor cell lines were maintained with Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) at 37°C, 5% CO 2 . Cell lines were routinely tested for mycoplasma presence. Isolation and characterization of MenSCs has been previously described [5] .
Experiments employing human PBMCs were approved by the ethics committees of the University Hospital of Bellvitge and the Blood and Tissue Bank from Catalonia. PBMCs of healthy donors were isolated from blood by ficoll (Rafer, Spain) density gradient centrifugation in Leucosep tubes (Greiner Bio-one, Kremsmünster, Austria) following the manufacturer's recommendations. T cells were isolated using the Rosette-Set Human T Cell Enrichment Cocktail (STEMCELL Technologies, Vancouver, Canada). For stimulation, T cells were cultured with CD3/ CD28-activating Dynabeads (Thermo Fisher Scientific) at 1:3 bead-to cell ratio.
The oncolytic adenovirus ICOVIR15 has been previously described [5] . ICOVIR15-cBiTE was engineered to express cBiTE gene under the control of the viral major late promoter by homologous recombination in bacteria, similarly to previous described for ICOVIR15K-BiTE [6] .
Production of supernatants
A549 or MenSCs (2.5 × 10 6 ) were infected with ICOVIR15 or ICOVIR15-cBiTE (MOI = 5 or 50, respectively) and supernatants were harvested 72 h after infection. For binding assays, supernatants were concentrated 20× with Amicon Ultra-15 filter units with a molecular weight cut-off of 30 kDa (Merck Millipore, Darmstadt, Germany). Supernatants from uninfected cells were used as a negative mock control.
Binding assay
Target cells (A549 cells, 2 × 10 5 ) were incubated with supernatants (generated from infected A549 cells) for 1 h on ice. Cells were stained with the monoclonal M2 anti-FLAG antibody (Sigma Aldrich, St. Louis, MO, USA) as primary antibody and a goat anti-mouse IgG as secondary antibody (Thermo Fisher Scientific). Cells were analyzed with a Gallios cytometer (Beckman Coulter, Brea, CA, USA). The FlowJo software (Tree Star, Ashland, OR, USA) was used for data analysis.
Virus cytotoxicity assays
Virus cytotoxicity assay was performed as previously described [6] . The inhibitory concentration 50 (IC 50 ) was calculated with GraphPad Prism v6.02 (GraphPad Software Inc.) by a dose-response nonlinear regression with a variable slope.
To assess the cBiTE-mediated cytotoxicity, A431-GL target cells (3 × 10 4 ) were cocultured with 1.5 × 10 5 T cells (E:T = 5) in 96-well plates. Cocultures were mixed with 100 μl of mock, ICOVIR15, or ICOVIR15-cBiTE supernatants (generated from MenSCs infected with the corresponding viruses). After 24 h of incubation, cocultures were trypsinized and stained with LIVE/DEAD (Thermo Fisher Scientific). Viable GFP-expressing tumor cells were determined by flow cytometry (negative for LIVE/DEAD and positive for GFP). CountBright Absolute Counting Beads (Thermo Fisher Scientific) were used for absolute cell number determination. Cytotoxicity was expressed as the percentage of live cancer cells in cocultures normalized to cancer cells cultured alone.
In vivo studies
In vivo studies were performed at the ICO-IDIBELL animal facility (Barcelona, Spain) AAALAC unit 1155 and approved by IDIBELL's Ethical Committee for Animal Experimentation.
Lung adenocarcinoma xenograft tumors were established by implanting 5 × 10 6 A549 cells subcutaneously into both flanks of 8-week-old NOD scid gamma (NSG) mice. When tumors reached 100-120 mm 3 , mice were randomized and distributed into groups. To evaluate systemic antitumor efficacy, 1 × 10 7 human allogeneic PBMCs were administered to the mice by intravenous injection. The next day, animals were treated with a single intraperitoneal dose of PBS, 1 × 10 10 vp/mice of OAdv (ICOVIR15 or ICOVIR15-cBiTE) or MenSC/OAdv (5 × 10 6 cells previously infected with ICOVIR15 or ICOVIR15-cBiTE at MOI 50 for 24 h).
Tumor volume was calculated according to equation
where W and L are the width and the length of the tumor, respectively. Data are expressed as the tumor size relative to the size at the beginning of the therapy (tumor growth). At the end of the study, animals were euthanized and tumors were collected. One half was frozen for DNA/RNA extraction, and the other half was fixed in 4% formaldehyde for 24 h and embedded in paraffin.
DNA/RNA quantification by qPCR
Frozen tumor samples were disrupted using a mortar and pestle under liquid nitrogen. RNA and DNA were isolated with the DNA/RNA/protein kit (IBI Scientific, Dubuque, IA, USA) from~25 mg of homogenized tissue. RNA samples were treated with the TURBO DNA-free kit (Thermo Fisher Scientific) to remove traces of genomic DNA. RNA (1 µg) was retrotranscribed with the HighCapacity cDNA Reverse Transcription kit (Thermo Fisher Scientific). Real-time analysis was performed in a LightCycler 480 Instrument II (Roche, Basel, Switzerland) in the presence of SYBR Green I Master (Roche). To quantify viral genomes and E1A/cBiTE transcripts in the tumor, 100 ng of DNA and 40 ng of cDNA were used, respectively. PCR conditions were 95°C 10 min, 40× cycles of 95°C 15 s, 60°C 1 min, and 72°C 7 min. Viral genome primers were Ad18852: 5′-CTTCGATGATGCCGCAGTG-3′ and Ad19047R: 5′-ATGAACCGCAGCGTCAAACG-3′. E1A primers were qE1AF: 5′-ATCGAAGAGGTACTGGCT GA-3′ and qE1AR: 5′-CCTCCGGTGATAATGACAAG-3′; cBiTE primers were qBiTEF: 5′-CGGCGAGAAAGTG ACAATGAC-3′ and qBiTER: 5′-TTGGTGAGGTGCCA CTTTTC-3′; and b-actin primers were ACBTF: 5′-CTGGAACGGTGAAGGTGACA-3′ and ACTBR 5′-GGGAGAGGACTGGGCCATT-3′. Standard curves for viral genomes were prepared by serial dilutions of known copy numbers of a plasmid containing the adenovirus genome. β-actin expression was used to normalize E1a and cBiTE gene expression. In all cases, nonretrotranscribed RNA samples, equivalent to the amount cDNA loaded in the PCR, were run to discard genomic DNA contamination.
Histology and immunohistochemistry
A549 paraffin-embedded sections (5-μm thickness) of tumors sample were treated with an anti-Ad2/5E1A (SC-430, Santa Cruz Biotechnology) as primary antibody.
Immunohistochemical staining was performed with EnVision (DAKO, Hamburg, Germany), according to manufacturers' instructions, and with hematoxylin. Images were acquired using the Nikon Eclipse 80i microscope running NIS elements BR software (Nikon Instruments Europe BV, Amsterdam, Netherlands).
Statistical analysis
Statistical comparisons between two groups were performed using the Mann-Whitney U test. For comparison of more than two groups, Kruskal-Wallis with Dunn post hoc test was used. Statistical significance was established as p < 0.05. Data are presented as the mean ± SD or SEM. All statistical analysis were calculated with GraphPad Prism software.
Results
Generation and characterization of ICOVIR15-cBiTE generated from infected MenSCs
The parental oncolytic adenovirus, ICOVIR15, has been previously described [5] . This virus is an E1a-Δ24-based oncolytic adenovirus with palindromic E2F binding sites in the E1a promoter and an insertion of Arg-Gly-Asp (RGD) in the HI-loop of the fiber knob that has shown a higher MenSCs infection capability [9] . We engineered this virus to express an EGFR-targeting bispecific T-cell engager (cBiTE) under the control of the adenovirus major late promoter (Fig. 1a) .
To evaluate whether cBiTE insertion affected viral oncolytic properties, a dose-dependent cytotoxicity assay was performed. As shown in Fig. 1b, ICOVIR15 -cBiTE retained oncolytic properties in vitro compared with its parental counterpart. We also compared virus production (both armed and parental virus) in MenSCs and A549 cell line (a highly permissive cell line commonly used for OAdv production). The total production of ICOVIR15 compared to ICOVIR15-cBiTE was similar for each cell line (mean of 4475 TU/cell versus 4185 TU/cell for ICOVIR15 and ICOVIR15-cBiTE on A549, and 2910 TU/cell versus 2475 TU/cell on MenSCs) indicating that cBiTE transgene insertion into ICOVIR15 genome does not affect total virus production (supplementary Fig. 1) . Moreover, similar lower viral production was determined for both virus in MenSCs compared to A549 (1.5 and 1.6-fold decrease in production for ICOVIR15 and ICOVIR15-cBiTE, respectively, in MenSCs compared to A549), as previously described [9] .
We next determined whether the cBiTE encoded by ICOVIR15-cBiTE was properly secreted by MenSCs infected cells while retaining its EGFR-antigen binding property. For this purpose, flow cytometry-based binding assays were performed by using the FLAG tag fused to the cBiTE. Correct cBiTE binding to A549-EGFR + was detected only in the supernatants of ICOVIR15-cBiTEinfected MenSCs (Fig. 1c) . We next investigated the cBiTE-mediated cytotoxicity in vitro. To avoid the interference of virus-mediated cytotoxicity, we chose as a target the A431-GL EGFR + cell line, which is partly resistant to adenovirus infection because of its low coxsackievirus-adenovirus receptor expression. A431-GL cells were cocultured with T-cells in the presence of supernatants obtained from noninfected (mock) or ICOVIR15/ICOVIR15-cBiTE-infected MenSCs. A significant cytotoxicity was observed after 24 h of incubation only in the presence of ICOVIR15-cBiTE supernatant (Fig.  1d ). This result indicates that once cBiTE is expressed and secreted from infected cells, it can successfully lead to Tcell-mediated cytotoxicity of EGFR-expressing cells.
ICOVIR15-cBITE-loaded MenSCs enhances in vivo antitumor efficacy
We have recently reported the tumor-homing properties and antitumor efficacy of ICOVIR15-loaded MenSCs after systemic administration in human tumor-bearing NSG mice in the presence of human PBMCs [9] . To determine whether cBiTE production from ICOVIR15-cBiTE infected MenSCs improved the previously described antitumor efficacy, NSG mice bearing subcutaneous A549 tumors were intravenously injected with human PBMCs and 24 h later intraperitoneally treated with PBS (control group), ICOVIR15, ICOVIR15-cBiTE, MenSCs/ICOVIR15 (MenSCs previously infected with ICOVIR15 at MOI 50 for 24 h), or MenSCs/ICOVIR15-cBiTE (MenSCs previously infected with ICOVIR15-cBiTE at MOI 50 for 24 h). During the first week after treatment, all groups showed a tendency to control tumor growth compared to the control group, but differences were only statistically significant for the MenSCs/ICOVIR15-cBiTE group. Notably, from day 7 until the end of the experiment, although MenSCs/ICOVIR15 demonstrated improved tumor growth control compared to PBS and ICOVIR15 groups (1.2-fold decrease versus both groups), only the group treated with MenSCs/ICOVIR15-cBiTE showed a significant reduction in tumor growth compared to PBS (1.9-fold decrease) and to other treatment groups (1.9, 1.7, and 1.6-fold decrease versus ICOVIR15, ICOVIR15-cBiTE, and MenSCs/ ICOVIR15, respectively) (Fig. 1e) . Histology analysis of the tumors at the end of the experiment revealed the expression of the E1a protein in tumors of animals treated with the oncolytic adenovirus ICOVIR15 and ICOVIR15-cBiTE alone or in combination with MenSCs, confirming the correct delivery and amplification of both viruses in tumors (Fig. 1f) . Moreover, transcript analysis of collected tumors indicated correct viral transcripts (E1a) production in OAdv treated animals and, as expected, transgene transcript (cBiTE) generation only in ICOVIR15-cBiTE treated animals (Fig. 1g) . However, when ICOVIR15-cBiTE was used, the amount of cBiTE transcripts was higher than the amount of E1a viral transcripts (Fig. 1g, white bars) , and lower viral load (Fig. 1h) at the end of the experiment for ICOVIR15-cBiTE groups (alone or using MenSCs as carriers) were observed. These results point a competitive scenario between viral genes and cBiTE in terms of transcription or translation. However, this reduced amount of cBiTE-armed virus was not correlated with a reduced antitumor activity, probably due to cBiTE effect.
Discussion
In 2016, we reported an initial clinical experience in the use of CELYVIR (autologous mesenchymal stem cells infected with ICOVIR5, a previous version of ICOVIR15, in children with advanced neuroblastoma (NCT01844661)) [10] .
Results from this clinical trial demonstrated good tolerance to the treatment and some clinical responses, including a complete remission. Over the last years, we have been trying to better understand the biology of MSCs after adenoviral infection and to develop an optimized CELYVIR version with enhanced antitumor properties and an easier production process. In previous work, we and others reported the advantages of using allogeneic MenSCs as cell carriers for OAdv tumor delivery [5, 9, 11] . Moreover, we pointed out the antitumor efficacy of MenSCs after OAdv infection in combination with human PBMCs. In this work, we aimed at further improving the antitumor potential of our strategy by combining MenSCs with an EGFR BiTE-armed OAdv [6] , Although the advantages of expressing BiTEs from genetically modified mesenchymal stem cells have been previously demonstrated [12] , this is the first report on the benefit of the combination of MenSCs, BiTE immunotherapy and OAdv.
Our results prove proper cBiTE production from OAdinfected MenSCs, and an increased in vitro and in vivo cytotoxicity, confirming the existence of an improved tumor growth control by the cooperative action between OAd, cBiTE, and MenSCs. Of special interest for us is the in vivo antitumor efficacy comparison between the cBiTEexpressing versus the nonexpressing OAdv in combination with MenSCs. Thus, the tumor growth difference between both groups is 7, 20, 2.3, and 1.6-fold decrease at day 4, 7, 11, and 14 post-treatment, respectively, being always in favor of the MenSCs/ICOVIR15-cBiTE group.
In summary, our results show that the combination of ICOVIR15-cBiTE and MenSCs could represent an attractive CELYVIR candidate for evaluation in clinical trials.
